Emerging small molecules for ulcerative colitis: clinical advancements and trial insights - PubMed
3 hours ago
- #clinical trials
- #inflammatory bowel disease
- #immunomodulators
- Ulcerative colitis (UC) is an inflammatory bowel disease with an unknown cause, managed with drugs like mesalazine for mild cases and corticosteroids, immunomodulators, or advanced therapies for moderate-to-severe forms, though achieving consistent and lasting responses remains difficult.
- This review focuses on emerging small molecules for UC, summarizing efficacy and safety data from recent phase II-III clinical trials, identified via literature searches on PubMed, Scopus, and ClinicalTrials.gov.
- Innovative therapies targeting alternative pathways, such as miRNA-124 upregulators, JAK inhibitors, S1P modulators, and LANCL2 agonists, may improve UC management, and combining small molecules with biologics could enhance effectiveness, reduce immunogenicity, and increase treatment durability.